Related Experiment Video
Updated: Nov 12, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Rheumatoid Arthritis, Statin Indication and Lipid Goals: Analysis According to Different Recommendations
Walter Masson1, Emiliano Rossi1, Rodolfo N Alvarado2
1Servicio de Cardiología, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199ABB Ciudad Autónoma de Buenos Aires, Argentina.
Insights
Cardiovascular risk in rheumatoid arthritis (RA) patients varies by strategy, with significant gaps in statin therapy and LDL-C goal achievement. Different guidelines yield different statin indications for RA patients.
Area of Science:
- Cardiology
- Rheumatology
- Public Health
Background:
- Cardiovascular disease (CVD) is a major concern for patients with rheumatoid arthritis (RA).
- Effective cardiovascular risk management strategies are crucial for RA patients.
- Current guidelines offer various approaches to managing cardiovascular risk in RA.
Purpose of the Study:
- To compare different cardiovascular risk assessment strategies in RA patients.
- To determine the proportion of RA patients eligible for statin therapy under various guidelines.
- To evaluate the achievement of lipid goals in RA patients based on European recommendations.
Main Methods:
- A cross-sectional study utilizing a secondary database.
- Estimation of cardiovascular risk using QRISK-3, Framingham, ASCVD, and SCORE calculators.
- Analysis of statin therapy indications based on NICE, Argentine Consensus, ACC/AHA, and European guidelines.
Main Results:
- Different guidelines resulted in varying eligibility for statin therapy (18.2%–41.1%).
- Only 24.7% (primary) and 48.7% (secondary) prevention patients were on statins.
- Under European guidelines, 50.0%, 46.2%, and 15.9% of low-moderate, high, and very high-risk patients met lipid goals, respectively.
Conclusions:
- Cardiovascular risk stratification and statin indication differ significantly across the four analyzed strategies in RA patients.
- A notable discrepancy exists between recommended and actual statin use.
- Few RA patients achieve their target LDL-C goals, highlighting a need for improved lipid management.
Background:
Different strategies have been proposed for the cardiovascular risk management of patients with rheumatoid arthritis (RA).
Objectives:
(1) To estimate the cardiovascular risk by different strategies in RA patients, analyzing which proportion of patients would be candidates to receive statin therapy; (2) to identify how many patients meet the recommended lipid goals.
Methods:
A cross-sectional study was performed from a secondary database. The QRISK-3 score, the Framingham score (adjusted for a multiplying factor×1.5), the ASCVD calculator and the SCORE calculator were estimated. The indications for statin therapy according to NICE, Argentine Consensus, ACC/AHA, and new European guidelines were analyzed. The recommended LDL-C goals were analyzed.
Results:
A total of 420 patients were included. In total, 24.7% and 48.7% of patients in primary and secondary prevention were receiving statins, respectively. Only 19.4% of patients with cardiovascular history received high intensity statins. Applying the ACC/AHA guidelines (based on ASCVD score), the Argentine Consensuses (based on adjusted Framingham score), the NICE guidelines (based on QRISK-3) and European recommendations (based on SCORE), 26.9%, 26.5%, 41.1% and 18.2% of the population were eligible for statin therapy, respectively. Following the new European recommendations, 50.0%, 46.2% and 15.9% of the patients with low-moderate, high or very high risk achieved the suggested lipid goals.
Conclusion:
Applying four strategies for lipid management in our population, the cardiovascular risk stratification and the indication for statins were different. A significant gap was observed when comparing the expected and observed statin indication, with few patients achieving the LDL-C goals.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease IV: Nursing Management
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis IV: Nursing Management
